Skip to main content

Increased concentration of serum soluble LAG3 in systemic lupus erythematosus

Background

In systemic lupus erythematosus (SLE), type I interferon and plasmacytoid DCs (pDCs) are supposed to play important roles. However, there are few evidences for pDCs activation in SLE. Murine pDCs are reported to produce soluble LAG3 (sLAG3) upon activation and pDCs are responsible for most of sLAG3 in mice serum [1]. Therefore, serum sLAG3 concentration was examined in SLE and other autoimmune diseases.

Materials and methods

This study enrolled 45 SLE patients who met ACR criteiria. Disease activity was rated using a SLE disease activity index (SLEDAI). sLAG3 concentrations were measured by a quantitative sandwich enzyme immunoassay [2].

Results

The ratio of sLAG3 concentration in SLE to control was 3.10+/-1.05, PM/DM to control was 1.04+/-0.08, and RA to control was 0.77+/-0.14. In addition, sLAG3 concentrations showed a significant correlation with SLEDAI. Interestingly, elevation of sLAG3 was observed even in patients with SLEDAI = 0. These results suggested that sLAG3 could be a specific and novel marker for SLE.

Conclusions

sLAG3 can be a novel marker for SLE. sLAG3 in sera of SLE patient may reflect the activation of pDCs. Because sLAG3 shows adjuvant effect when combined with active immunization [3], sLAG3 may contribute to the exacerbation of lupus. The association between elevated sLAG3, type I interferon signature and activation of pDCs should be investigated further.

Figure 1
figure1

sLAG3 concentrations in SLE and other autoimmune diseases measured by ELISA.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Seri Yu.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Yu, S., Fujio, K., Ishigaki, K. et al. Increased concentration of serum soluble LAG3 in systemic lupus erythematosus. Arthritis Res Ther 14, P16 (2012). https://doi.org/10.1186/ar3617

Download citation

Keywords

  • Systemic Lupus Erythematosus
  • Interferon
  • Systemic Lupus Erythematosus Patient
  • Active Immunization
  • Activity Index